Evidence map›Paper›PMID 36540895›Full record

ArticleJournal of analytical oncology2022

A Study to Investigate the Role of Noncoding RNA miR146 Alpha as a Potential Biomarker in Prostate Cancer.

Myla Worthington, Chelsey Aurelus, Narendra Banerjee, Christopher Krauss, William Kahan, Satyendra Banerjee, Sherita Gavin, Victoria Bartlett, Gloria Payne, Jeffrey Rousch and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of analytical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Myla WorthingtonDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Chelsey AurelusDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Narendra BanerjeeDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Christopher KraussDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
William KahanDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Satyendra BanerjeeDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Sherita GavinDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Victoria BartlettDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Gloria PayneDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Jeffrey RouschDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.
Mukesh VermaDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Suite 4E102, 9609 Medical Center Drive, Bethesda, USA.
Fazlul SarkarDepartment of Pathology, Wayne State University and Barbara Karmanos Cancer Center, Detroit, USA.
Hirendra Nath BanerjeeDepartment of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA.

Funding

Elizabeth City State University Minority Access to Research Careers (E-MARC) UndeT34GM100831 · NIGMS · ELIZABETH CITY STATE UNIVERSITY · PI BANERJEE, HIRENDRA N · 2012 to 2022
$1.9M
Mechanistic Role of miRNAs and Their Targets in Prostate Cancer AggressivenessR01CA164318 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2012 to 2015
$1.3M
NCI NIH HHS R01 CA164318NIGMS NIH HHS T34 GM100831
6 · The paper itself

Abstract

There is a need for additional biomarkers for the diagnosis and prognosis of prostate cancer. MicroRNAs are a class of non-protein coding RNA molecules that are frequently dysregulated in different cancers including prostate cancer and show promise as diagnostic biomarkers and targets for therapy. Here we describe the role of micro RNA 146 a (miR-146a) which may serve as a diagnostic marker for prostate cancer, as indicated from the data presented in this report. Also, a pilot study indicated differential expression of miR-146a in prostate cancer cell lines and tissues from different racial groups. This report provides a novel insight into understanding the prostate carcinogenesis.

Indexed as

BiomarkermiR146 alphaNon Coding RNAProstate Cancer

Identifiers

PMID36540895
PMCPMC9762859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.